Press release
Ankylosing spondylitis Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
Ankylosing spondylitis Treatment Market
(Albany, USA) DelveInsight's "Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
The Ankylosing spondylitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.
To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ankylosing spondylitis Market Forecast [https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Ankylosing spondylitis Market Report:
* The Ankylosing spondylitis market size was valued at USD 4200 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In November 2023, UCB announced new long-term data from the BIMZELX (bimekizumab) Phase IIb study BE AGILE and its open-label extension (OLE). Patients with ankylosing spondylitis (AS) treated with bimekizumab, an IL-17A and IL-17F inhibitor, demonstrated sustained improvements in signs and symptoms, disease activity, physical function, and health-related quality of life for up to five years, maintaining a consistent safety profile throughout the treatment period. These findings were presented at the American College of Rheumatology (ACR) Convergence 2023.
* In 2023, the total prevalent population of ankylosing spondylitis in the 7MM region was approximately 2,300,000, with the highest number of cases observed in the United States.
* In the 7MM, approximately 1,130,000 cases of diagnosed ankylosing spondylitis were reported in 2023. According to the analysis, these cases are projected to increase by 2034 with a moderate compound annual growth rate (CAGR).
* In 2023, the United States reported the highest number of age-specific prevalent cases, with approximately 270,000 cases among individuals aged 40-59 years, followed by those under 40 years of age.
* In 2023, Italy had the highest number of diagnosed prevalent cases of ankylosing spondylitis in the EU4 region, totaling approximately 192,000 cases.
* Key Ankylosing spondylitis Companies: Galapagos NV, Affibody Therapeutic/Inmagene Biopharmaceuticals, Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others
* Key Ankylosing spondylitis Therapies: JYSELECA (filgotinib), ABY-035 (izokibep), 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others
* The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females
Ankylosing spondylitis Overview
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain and stiffness. Over time, AS can cause the vertebrae in the spine to fuse, resulting in a loss of flexibility and a hunched-forward posture. In severe cases, it can lead to the spine becoming inflexible and rigid.
Get a Free sample for the Ankylosing spondylitis Market Report - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Market
The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Ankylosing spondylitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Ankylosing spondylitis Epidemiology Segmentation:
The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalent cases of Ankylosing Spondylitis in the 7MM
* Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
* Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in 7MM
* Treated cases of Ankylosing Spondylitis in the 7MM
* Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
* Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM
Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ Ankylosing spondylitis Epidemiological Insights [https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Ankylosing spondylitis Therapies and Key Companies
* JYSELECA (filgotinib): Galapagos NV
* ABY-035 (izokibep): Affibody Therapeutic/Inmagene Biopharmaceuticals
* 608 Dose A: Sunshine Guojian Pharmaceutical
* Jaktinib: Suzhou Zelgen Biopharmaceuticals
* AK111: Akeso
* BCD-085: Biocad
* Jitongning tablets: Tasly Pharmaceutical
* Golimumab: Hanyang University Seoul Hospital
* Bimekizumab: UCB Biopharma SRL
* Upadacitinib: AbbVie
* Ixekizumab: Eli Lilly and Company
Request for sample report @ Ankylosing Spondylitis Clinical Trials [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Ankylosing spondylitis Market Strengths
* Certain initiatives have been taken by private and government organizations to raise awareness about the disease. The Spondylitis Association of America (SAA) began officially celebrating SpA Awareness Month in May.
* There has been an increase in pharmaceutical companies' investment in the research and development of drugs.
Ankylosing spondylitis Market Opportunities
* Several pharmaceutical key players have taken the initiative to meet the unmet needs of the Ankylosing Spondylitis market's present situation.
* The prevalence of Ankylosing Spondylitis diagnosis codes more than doubled between 2006 and 2016; increase in prevalence creates a lucrative opportunity for the Ankylosing Spondylitis market.
Scope of the Ankylosing spondylitis Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Ankylosing spondylitis Companies: Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others
* Key Ankylosing spondylitis Therapies: JYSELECA (filgotinib), ABY-035 (izokibep), 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others
* Ankylosing spondylitis Therapeutic Assessment: Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies
* Ankylosing spondylitis Market Dynamics: Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Ankylosing spondylitis Unmet Needs, KOL's views, Analyst's views, Ankylosing spondylitis Market Access and Reimbursement
Discover more about therapies set to grab major Ankylosing spondylitis market share @ Ankylosing spondylitis Treatment Landscape [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Ankylosing spondylitis Market Report Introduction
2. Executive Summary for Ankylosing spondylitis
3. SWOT analysis of Ankylosing spondylitis
4. Ankylosing spondylitis Patient Share (%) Overview at a Glance
5. Ankylosing spondylitis Market Overview at a Glance
6. Ankylosing spondylitis Disease Background and Overview
7. Ankylosing spondylitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ankylosing spondylitis
9. Ankylosing spondylitis Current Treatment and Medical Practices
10. Ankylosing spondylitis Unmet Needs
11. Ankylosing spondylitis Emerging Therapies
12. Ankylosing spondylitis Market Outlook
13. Country-Wise Ankylosing spondylitis Market Analysis (2020-2034)
14. Ankylosing spondylitis Market Access and Reimbursement of Therapies
15. Ankylosing spondylitis Market Drivers
16. Ankylosing spondylitis Market Barriers
17. Ankylosing spondylitis Appendix
18. Ankylosing spondylitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ankylosing-spondylitis-treatment-market-2034-clinical-trials-medication-prevalence-incidence-therapies-ema-pdma-fda-approvals-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/rare-diseases
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ankylosing spondylitis Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight here
News-ID: 3746814 • Views: …
More Releases from ABNewswire
RC Adventures, LLC Opens Community-Focused Hobby Shop with Indoor Rock Crawling …
RC Adventures, LLC has opened its doors as a comprehensive remote control hobby destination featuring both brick-and-mortar and online shopping experiences. The new store distinguishes itself with an indoor rock crawling course, dedicated kids' sandbox, construction equipment dirt area, and rental services, creating a community hub for RC enthusiasts of all ages and skill levels.
RC Adventures, LLC has officially launched operations as a full-service remote control hobby destination, combining traditional…
Caneca Coffee Roasters Launches with Experiential Approach to Specialty Coffee, …
Caneca Coffee Roasters has entered the specialty coffee market with a distinctive philosophy that positions every bean as a story and every cup as a transformative journey. The new roastery offers carefully crafted blends including Shanta's Fruit, Golden Dawn Blend, Espresso Blend, House Blend, and a bold DECAF option, each designed to capture vibrant flavors from the world's finest coffee-growing regions.
Caneca Coffee Roasters has officially launched operations with an experiential…
Atlanta's Trio Tailoring, LLC Celebrates Over a Decade of Making Custom Clothing …
Trio Tailoring, LLC marks more than ten years of serving Atlanta's professional community with affordable, high-quality custom clothing. The established clothier has become the go-to destination for wedding grooms, attorneys, and corporate professionals seeking personalized garments that deliver exceptional value without compromising on craftsmanship or style.
Since establishing its presence in Atlanta's fashion and professional apparel market over a decade ago, Trio Tailoring, LLC has built a loyal following among discerning…
Dr. Chris Chlebowski Introduces Axobotanica, a New Product and Education Brand B …
Internationally recognized educator and speaker Dr. Chris Chlebowski is bringing his two decades of professional experience to consumers through Axobotanica-a family-owned retail and education brand offering thoughtfully crafted products and clear, trustworthy information. The company reflects a commitment to quality, transparency, and meaningful customer experiences.
Axobotanica LLC launches as a new product and education brand shaped by nearly twenty years of professional experience. Co-founded by Dr. Chris Chlebowski, the platform blends…
More Releases for Ankylosing
Ankylosing Spondylitis Market Trends That Will Shape the Next Decade: Insights f …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Ankylosing Spondylitis Market Size By 2025?
The valuation of the ankylosing spondylitis sector has experienced robust expansion over the past few years, projected to advance from a figure of $5.9 billion in the year 2024 up to $6.34 billion by 2025, reflecting a compound annual…
Ankylosing Spondylitis Market Surges With The Growing Geriatric Population World …
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Ankylosing Spondylitis Market Size and Its Estimated Growth Rate?
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
Ankylosing Spondylitis Uncovered: Market Dynamics and Future Projections
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/2638
Introduction:
The global ankylosing spondylitis market has been on a steady rise, reflecting the growing awareness and prevalence of this inflammatory condition. With a remarkable market size of $5,140.94 million in 2020, the projections indicate a substantial leap to $8,110.59 million by 2030. Ankylosing spondylitis, often misunderstood, is a complex disorder that affects the spine's flexibility and posture, potentially leading to severe complications if not managed effectively.
Unveiling Ankylosing…
Ankylosing Spondylitis Treatment Market to Witness Astonishing Growth by 2029
This Ankylosing Spondylitis Treatment Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry sector. Future development visions and a wide range of subjects are covered in this Ankylosing Spondylitis Treatment Market study report.…
Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/
Retail Pharmacy to Dominate the…
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027.
Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631
Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen…
